143 related articles for article (PubMed ID: 17881638)
21. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders.
Randi ML; Lombardi AM; Scapin M; Tezza F; Scandellari R; Ruzzon E; Duner E; Fabris F
Thromb Haemost; 2007 Sep; 98(3):702-4. PubMed ID: 17849070
[No Abstract] [Full Text] [Related]
22. Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.
Ware AD; Birkness J; Duffield AS; Gocke CD
Virchows Arch; 2018 Jul; 473(1):131-135. PubMed ID: 29611054
[No Abstract] [Full Text] [Related]
23. Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?
Kelly K; McMahon C; Langabeer S; Eliwan H; O'Marcaigh A; Smith OP
Blood; 2008 Nov; 112(10):4356-7. PubMed ID: 18988882
[No Abstract] [Full Text] [Related]
24. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
25. Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis.
Jain S; Harrison C; McMullin MF; Houston RF
Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):893. PubMed ID: 20692135
[No Abstract] [Full Text] [Related]
26. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
27. JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosis.
Thachil J; Hawkins S; Woodcock B
Br J Haematol; 2011 Mar; 152(6):675. PubMed ID: 21219299
[No Abstract] [Full Text] [Related]
28. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
29. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
30. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
31. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
32. IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house.
Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Minervini CF; Brunetti C; Impera L; Ricco A; Cellamare A; Specchia G; Albano F
Ann Hematol; 2014 Sep; 93(9):1605-7. PubMed ID: 24408161
[No Abstract] [Full Text] [Related]
33. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.
Rao N; Butcher CM; Lewis ID; Ross DM; Melo JV; Scott HS; Bardy PG; D'Andrea RJ
Br J Haematol; 2012 Jan; 156(2):268-70. PubMed ID: 21859430
[No Abstract] [Full Text] [Related]
34. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
35. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Olcaydu D; Skoda RC; Looser R; Li S; Cazzola M; Pietra D; Passamonti F; Lippert E; Carillo S; Girodon F; Vannucchi A; Reading NS; Prchal JT; Ay C; Pabinger I; Gisslinger H; Kralovics R
Leukemia; 2009 Oct; 23(10):1924-6. PubMed ID: 19440215
[No Abstract] [Full Text] [Related]
36. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
37. Chorea in the elderly with mutation positive polycythemia vera: a case report.
Kumar H; Masiowski P; Jog M
Can J Neurol Sci; 2009 May; 36(3):370-2. PubMed ID: 19534341
[No Abstract] [Full Text] [Related]
38. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
39. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.
Regina S; Herault O; D'Alteroche L; Binet C; Gruel Y
J Thromb Haemost; 2007 Apr; 5(4):859-61. PubMed ID: 17403204
[No Abstract] [Full Text] [Related]
40. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
